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Human interferons inhibit experimental metastases of a human
melanoma cell line in nude mice
P. Ramani & F.R. Balkwill
Imperial Cancer Research Fund Laboratories, PO Box No. 123, Lincoln's Inn Fields, London WC2A 3PX, UK.
Summary Therapy with human lymphoblastoid interferon HuIFN-a(NI), or recombinant human interferon
gamma, rHuIFN-y, inhibited experimental pulmonary metastases of the human melanoma cell line,
DX3-azac, in BALB/c nude mice and significantly prolonged survival. The human IFNs had no effect on
nude mouse lung and spleen NK cell activity, lung macrophage activity, haemoglobin or white cell counts.
HuIFN-a(NI) had no effect on the levels of the IFN induced enzyme 2-5A synthetase in nude mouse lungs
although the rHuIFN-y caused some elevation. In addition, clearance of radiolabelled DX3-azac cells was
identical in control or human IFN treated mice, and there was no histological evidence of an increase in
immune effector cells associated with the metastatic lesions in treated mice. Human IFN therapy did not
affect the state of differentiation of the melanoma cells in vivo as measured by melanin content, but both
IFNs inhibited the development of colonies of DX3-azac cells in vitro. We conclude that in this model system
IFNs have direct anti-proliferative effects on metastatic cells.
Interferons, IFNs, have anti-tumour activity in a small
number of primary malignancies derived from cells of the
haemopoietic system (Spiegel, 1987). As IFNs can inhibit
metastasis in experimental animal models they may have
potential in eliminating micrometastasis and preventing
further tumour spread in human cancer. Interferons are
pleiotropic molecules that exert a variety of regulatory
actions on many cells of the body, but the ways in which
they act against tumours are not fully understood. Inter-
ferons can exert many direct effects on the tumour cells.
They are cytostatic and cytotoxic from normal and tumour
cells (Balkwill et al., 1982, 1985; Taylor-Papadimitriou,
1980), they can alter the state of tumour cell differentiation
(Rossi, 1985), modulate surface antigen expression (Rosa et
al., 1986), inhibit oncogene/expression and levels of onco-
gene product (Jonak & Knight, 1986), and induce reversion
of the transformed phenotype to a normal phenotype
(Brouty-Boye & Gresser, 1981). All these direct actions may
play a role in limiting tumour spread.
Interferons can also act on the tumour via their action on
host defence cells (Gresser & Bourali-Maury, 1972; Gresser
& Tovey, 1978; Gresser, 1985). NK. macrophage and T cell
functions can be stimulated by IFNs (reviewed by Freidman
& Vogel, 1983). Several workers have shown that pre-
treatment of mice with IFNs or IFN inducers prevents the
establishment of experimental metastasis (Hanna & Burton,
1981; Brunda et al., 1984; Nishimura et al., 1985). However,
there are relatively few reports concerning the antimetastatic
effects of IFNs in metastases models when IFNs are given
after the tumour challenge. Gresser & Bourali-Maury (1972)
showed that impure murine IFN could inhibit the develop-
ment of pulmonary metastases from subcutaneous tumours
of Lewis lung carcinoma. Glasgow & Kern (1981) found that
partially pure IFN initiated shortly after i.v. inoculation
inhibited the pulmonary metastases of murine osteogenic
sarcoma. Recently, Ramani et al. (1986) demonstrated the
pure recombinant hybrid human IFN alpha, rHuIFN-x A/D,
an IFN that has cross reactivity on mouse cells, significantly
inhibited the establishment and development of pulmonary
metastases of a mouse colon carcinoma.
The stimulation of host NK cells by IFNs has been
implicated in the protection of animals from metastatic
spread (Hanna & Burton, 1981; Brunda et al., 1984;
Nishimura et al., 1985). However, in the COLON 26 model
of murine metastasis we have found no evidence for the
involvement of host T cells, B cells or NK cells (Ramani et
al., 1986 and unpublished results) in the antimetastatic effect
of rHuIFN-x A/D.
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Human tumour xenografts growing in nude mice serve as
good models to dissociate the direct effects on human
tumour from indirect effects on the murine host because of
species specificity of the IFNs. Balkwill et al. (1982, 1985)
have shown that HuIFNs directly inhibit the growth of
subcutaneous human bowel, breast, lung and ovarian cancers
in nude mice.
As part of our studies into the antimetastatic actions of
IFNs we decided to extend the nude mouse human tumour
xenograft studies to an experimental metastases model.
Transplanted human tumours do not metastasize easily in
the nude mouse in spite of their aggressiveness in man. In
our studies, we therefore used a variant of a human mela-
noma cell line, DX3, which had been selected from the
parent line by treatment with the nucleoside analogue 5
azacytidine (5-azac) and serial passage in BALB/c nude mice.
The selected variant DX3-azac LT5.1 showed a 40-fold
increase in metastatic capacity (Ormerod et al., 1986).
Materials and methods
Mice
Inbred BALB/c mice (6-8 weeks) were obtained from the
ICRF breeding unit and housed in negative pressure
isolators.
Cells
DX3-azac LT5.1, derived from DX3, a human melanoma
cell line treated with azacytidine, was obtained from J.
Ormerod, ICRF (Ormerod et al., 1986). The cells were
grown in Eagle's medium (E4) supplemented with 10%
foetal calf serum (FCS).
Interferons
HuIFN-a (NI) (Wellferon) derived from Namalwa cells was
kindly supplied by Wellcome Research Laboratories, Langley
Court, Beckenham, Kent. This IFN was more than 99%
pure and its specific activity ranged from 1.17 to
2.20 x 108u mg . Recombinant human interferon gamma,
rHuIFN-y (Immuneron) was kindly supplied by Biogen
(Geneva, Switzerland). This IFN was more than 99% pure
and had a specific activity of 2 x 108 umg- . Partially puri-
fied C243 MuIFN-cx/f (Proietti et al., 1986) had a specific
activity of 1.3 x 108 umg- . These IFNs were assayed in
biological assay that measured reduction in viral RNA
synthesis and were calibrated against British reference
standard 69/19 (NIBSC, Hampstead, UK) or human IFN
standard Gg 23-901-530 or mouse reference standard C002-
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904-511 (National Institute of Allergy and Infectious Dis-
ease, NIH, Bethesda, MD) as described by Ramani et al.
(1986).
Experimental metastasis assay
Single cell suspensions of 5 x 105 cells were injected in 0.2ml
aliquots into lateral tail vein of each mouse. After 5 to 6
weeks, the mice were killed, the lungs were removed, and
macroscopic lung metastases enumerated (Ramani et al.,
1986).
Quantitative analysis of tumour cell arrest and survival
DX3-azac cells in the mid-log phase were incubated with
0.3 1iCi of 125Iodo-deoxyuridine (specific activity, 200mCi
mmol-1, Amersham International UK) ml-1 of medium for
24h. Cells were harvested and 5 x105 were injected i.v. in
0.2ml PBSA per mouse, followed by 2 x 105 units HuIFN-a
(NI) s.c. or rHuIFN-y i.p. Control mice were injected with
BSA/PBSA (3mgml-1). Mice were killed 2h, 24h, 48h and
72h after tumour cell injection and the lungs, liver, spleen
and kidney removed. The radioactivity for each individual
organ was determined in a gamma counter.
Cellular growth inhibition in vitro
103 DX3-azac cells were incubated at 37°C in 2ml E4+ 10%
FCS in 35mm Petri dishes with various concentrations of
HuIFN-a (Ni) or rHuIFN-y. The medium and IFN was
changed twice a week. After 3 weeks, individual colonies
were fixed in formal saline for 5min and stained with 1%
crystal violet for 2min.
Spleen and lung NK assay
The pulmonary tissue was digested with Collagenase Type 1
(Sigma, Poole, Dorset, UK) and Deoxyribonuclease Type 1
(Sigma, Poole, Dorset, UK) by incubating at 37°C for 1 h to
obtain host effector cells. YAC lymphoma target cells were
labelled with 200 uCi 51Cr (Amersham International UK,
specific activity 250-500mCimg-1 chromium). NK cell
activity was expressed as % cytotoxicity using the following
formula:
Test cpm - spontaneous release cpm
x 100.
Total cpm - spontaneous release cpm
Lung macrophage assay
The effector cells from enzyme-digested lungs were purified
by adherence purification (Dougherty et al., 1986) and
macrophages (greater than 80% viability) were plated in
various concentrations in 96 well microplates (Falcon, Becton
Dickinson). COLON 26 cells labelled with 200 uCi 3H thymi-
dine (specific activity, 25Cimmol-1, Amersham Internatio-
nal UK) were added and plates incubated for 48 h at 37°C.
Samples (100,p1) were removed from each well for scintilla-
tion counting and % cytotoxicity was calculated as for NK
cell assays above.
2-5A Synthetase assay
The principle of this assay involves the generation of oligo-
nucleotides from ATP in the presence of double stranded
RNA (poly I:C) by the IFN induced enzyme 2-5A syn-
thetase. These oligonucleotides can be assayed by their
ability to activate an endonuclease (obtained from L cells)
which cleaves ribosomal RNA to yield a distinctive pattern
of products. The post-mitochondrial S-10 fractions prepared
from the lungs and spleens of mice were incubated at room
temperature with 10,ul poly (I:C) and 30,u1 ATP to generate
2-5A (ppp) oligonucleotides. Dilutions (5lul) of standards (3,
10, 30nM) and sample dilutions were incubated with L cell
S-10 for 1 h. RNA was extracted and analysed by electro-
phoresis on agarose gels (Silverman et al., 1983). Electro-
phoresis was carried out at 100V (Power pack EC3000/
150m Pharmacia) for 2h. The end point dilution of the test
was compared to the cleavage seen in 1 nM standard and the
2-5A activity expressed as pmolATP260 o.d. - h-.
Immunoperoxidase technique (Hsu et al., 1981)
Frozen sections of lungs bearing DX3-azac tumours were
fixed in cold acetone for 10min and endogenous peroxidase
was blocked by 1% H202 in methanol. The endogenous
biotin was blocked with avidin 0.2mgml-1 (Sigma, Poole,
Dorset, UK) for 20min followed by biotin 0.1 mgml -1
(Sigma, Poole, Dorset, UK) for similar period. The sections
were incubated with primary antibody for I h, washed with
PBS and incubated with goat anti-rat IgG biotin conjugate
(Sigma, Poole, Dorset, UK) at a dilution of 1:20 for 30min
followed by DAKA ABC biotinylated horse-radish peroxi-
dase (dil. 1:100) after a 10min wash with PBS. The reaction
was developed with diaminobenzidine (Sigma, Poole, Dorset,
UK) counterstained with haematoxylin, dehydrated in alco-
hol and mounted in gelvatol.
Results
Effect of HuIFN-ac (NJ) or rHuIFN-y on the experimental
metastases of DX3-azac in BALBIc nude mice
BALB/c nude mice, 6 to 8 weeks old, were injected i.v. with
5 x 105 DX3-azac cells. Therapy with 2 x I05 UHuIFN-a N1,
s.c., or 2 x 10 U rHuIFN-y, i.p., was started within 2h of
tumour cell injection and given daily 5 days a week for 5
weeks. Each experiment was repeated 3 times. Table I shows
a typical experimnent in which both HuIFN-a (NI) and
rHuIFN-y had a significant (P=0.004) inhibitory effect on
the number of lung tumour nodules (median no.,
control=75, HuIFN-ax (Nl)= 1, rHuIFN-y=6). Lung
tumour burden was also decreased in treated mice (median
lung wts, control=200mg, HuIFN-a (Ni)= 140mg,
rHuIFN-y= 145mg, P=0.05).
Table I also shows the dose scheduling effect of HuIFN-cx
(N1) on the experimental metastases of DX3-azac. The
maximum therapeutic effect was seen when therapy with
IFN was started on the same day as injection of tumour
cells. However, inhibition in the number of pulmonary
nodules was also seen when therapy was started as late as 7
days after tumour cell injection (P=0.004) but if therapy
was initiated 14 days after tumour cell injection no inhibition
(P=0.1) of tumour nodules was seen (median lung nodules,
control=75, day 3= 13, day 7=31, day 14=68).
To see if the HuIFNs affected the survival of mice bearing
pulmonary metastases of DX3-azac, treatment was stopped
after 5 weeks and the mice killed when they showed signs of
respiratory distress. As shown in Figure 1, HuIFNs signifi-
cantly (P=0.005) increased the mean survival time
(control = 14.2 weeks, HuIFN-a (N1)= 17.0 weeks, rHuIFN-
y= 16.5 weeks). Mice in both the groups died of recurrent
tumours.
Characterization of cells in the lung tumour nodules
Routine histology of the lungs (H&E staining) showed the
presence of metastatic nodules composed of groups of large
pleomorphic cells in the lungs of control mice and those
treated with HuIFNs. IFN therapy reduced the size and
number of metastases but did not alter the morphology of
the tumours. There was no increase in the melanin content
in the IFN treated groups as assessed by staining with
Masson Fontana. A few mononuclear cells were associated
with some of the tumour nodules in the lungs of control and
IFN treated mice. These cells were characterized with the
monoclonal antibodies: F4/80 (Hume et al., 1983), which
reacts with mouse macrophages, TIB 120 (Springer et al.,
1981), which recognises Ia antigen on B cells, macrophages,
activated T cells, and anti-Thyl.2 (Herberman et al., 1979),
which is directed against T cells and NK cells).352 P. RAMANI & F.R. BALKWILL
Table I Effect of HuIFN-a (N1) or rHuIFN-y on development of experimental metastases of DX3-azac in
BALB/c nude mice
Lung nodules Weights of lungs (mg)
Initiation
Treatment of therapy Median Range Median Range
Control - 75 (2-200) 200 (140-390)
HuIFN-ac (Ni) (2 x 105 units) day 0 la (2-30) 140b (120-160)
HuIFN-ac (NI) (2 x 105 units) day 3 13a (0-38) 205 (120-230)
HuIFN-o (NI) (2 x 105 units) day 7 3la (0-100) 190 (150-470)
HuIFN-oa (Ni) (2 x 105 units) day 14 68 (38-78) 190 (140-480)
HuIFN-y (2x 105 units) day 0 6a (0-40) 145c (130-500)
5 x 105 DX3-azac cells were injected i.v. on day 0 and treatment with HuIFN-cx (Ni) s.c. or rHuIFN-y i.p.
started with 2h of tumour cell injection. Mice were killed after 5 weeks treatment. 12-14 mice were used per
group. Each experiment was performed 4 times. aThe number of lung nodules was significantly different from
control mice (P=0.004); bThe lung weights of mice treated with HuIFN-a (NI) were significantly different
from control mice (P=0.06); cThe lung weights of mice treated with rHuIFN-y were significantly different
from control mice (P=0.05).
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Figure 1 Percentage survival of mice injected with DX3-azac
cells: (--O--) mice treated with 0.2ml BSA/PBSA (3mgml-1);
(* ) mice treated with 2 x 105 units HuIFN-a (NI);
(* ) mice treated with 2 x 105 units rHuIFN-y. Therapy
was initiated 2h after tumour cell injection and continued daily
for 5 weeks. 12-14 mice were used per group. Each experiment
was repeated 4 times.
F4/80 positive and TIB 120 positive cells with morphology
characteristic of macrophages, occasional Thy 1-2 positive
(presumably NK cells) and a few TIB 120 lymphoid cells
were present in tumour nodules in both the groups. A
semiquantitative estimate of the cells infiltrating the tumours
showed no characteristic differences in numbers or distribu-
tion between mononuclear cells in control and IFN treated
groups.
Effect of the clearance of radiolabelled cells
In vivo clearance of radiolabelled DX3-azac cells was
measured in control mice and mice treated with HuIFNs.
Figure 2 represents the data from one of 3 similar experi-
ments. As shown, all i.v. injected cpm were localised to the
lungs by 10min. By 2h, 82% of the total injected cpm
remained in the lungs and thereafter, the retention of
radiolabelled cells was identical in control mice and mice
treated with HuIFN-o (NI) or rHuIFN-y. This suggested
that HuIFNs had no effect on the nude mouse organ
associated effector cells in vivo. By 72h less than 1% of the
total injected cpm survived in the lungs of control mice and
mice treated with either IFN.
Effect of HuIFNs on nude mouse NK cell activity
Host lung NK cell activity was measured after treatment
with 2 x 105 units HuIFN-ac (NI) s.c. or 2 x 105 units
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Figure 2 Clearance rates of 125lodo-deoxyuridine-labelled DX3-
azac cells: ( 0 -) mice treated with 0.2ml BSA/PBSA
(3 mgml-1); ( * ) mice treated with 2 x 105 units
HuIFN-a (NI); ( * ) mice treated with 2 x 105 units
rHuIFN-y. Each point represents a mean cpm in lungs of 5
individual animals.
rHuIFN-y i.p. given daily for 4 days after i.v. injection of
DX3-azac cells. The data presented in Table II is representa-
tive of 3 typical experiments. As shown, the doses of
HuIFNs used in this study had no effect on the nude mouse
lung NK cell activity (% lung cytotoxicity at effector target
ratio of 100:1, mean+s.d., control=28+1, HuIFN-a
(Nl)=27+0.8, rHuIFN-y=28+0.9). Stimulation of NK cell
activity was seen when mice were treated with rHuIFN-
aA/D a hybrid IFN with equal activity on human and
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Table II Effect of HuIFN-cs (NI) or HuIFN-y on lung macrophage luna NK cytotoxicity in BALB/c
nude mice
% Cytotoxicity±s.d. Effector:target cell ratio
Macrophage NK
20:1 10:1 100.1 40.1
Control 15.4+0.9 8.3+0.2 27.8+1 18.4+1
HuIFN-oa (Ni) (2 x 105 units) 13.2+1 5.4+0.4 26.9+0.8 17.9+1
rHuIFN-y (2 x 105 units) 14 +0.6 7.1+0.5 28.0+0.9 18.1+4
rHuIFN-cx A/Da (105 units) N.D. N.D. 38.1+1 26 +0.4
Mice were treated with daily HuIFN-oa (NI) s.c. or rHuIFN-y i.p. daily for 4 days. Control mice
were injected with 0.2ml PBSA/BSA s.c. daily for 4 days. Four mice were used per group. Each point
represents the mean results of 3 groups of mice. COLON 26 were used as targets. arHuIFN-a A/D has
equal activity on murine and human cells (Rehberg et al., 1982).
Effect of the lung macrophage activity of nude mice
The effect of HuIFNs on the lung macrophage cytotoxicity
was also measured after 4 days. Table II demonstrates the
data from one of 3 similar experiments. There was no
difference in the lung cytotoxicity between control mice and
mice treated with HuIFN-a (Ni) or rHuIFN-y (% macro-
phage cytotoxicity at effector target ratio 20:1,
control= 15+0.9, HuIFN-a (Ni)= 13.2+1, HuIFN-y=
14+0.6).
Effect of HuIFN therapy on nude mouse tissue 2-5A
synthetase levels
The 2-5A synthetase activity was measured as another
marker of the biological effect of HuIFN-ao (N1) or
rHuIFN-y on host cells. 2-5A synthetase levels in the spleens
and the lungs were assayed after 4 days of daily treatment
with 2 x 105 units HuIFN-a (NI) s.c., or 2 x 105 units
rHuIFN-y i.p. Mice treated s.c. with 2 x 105 units MuIFN
oc/,B were used as positive controls. As shown in Table III
there was no increase in the enzyme levels in either the lungs
or the spleens after treatment with HuIFN-ac (N1). Treat-
ment with rHuIFN-y resulted in a slight but insignificant
increase (P=0.1) in the lungs and spleen levels of the
enzyme in comparison to the levels seen in mice treated with
MuIFN a/,i.
Effect of human IFNs on haematological parameters
There was no statistical difference in the haemoglobin con-
tent (gdl-1, mean+s.d., control= 16.9+1.1, HuIFN-a
(Nl)= 16.4+ 1.0, rHuIFN-y = 16.4+0.9) or white cell counts
(106ml-1, mean+s.d., control =5.75 +0.3, HuIFN-a
(N1) =5.4+0.4, rHuIFN-y=5.9 +0.3) in samples taken by
bleeding tail veins after 4 days of daily treatment with either
HuIFNs.
Table III Levels of 2-5A synthetase in the mouse lung and spleen
Sp. activity
(pmol ATP/OD 260-1h-1)
Lung mean Spleen mean
Control <1 2
MuIFN-oe/# (2 x 105 units) 3.9a 32b
HuIFN-ac (NI) (2 x 105 units) < 1 1.97
HuIFN-y (2 x 105 units) 2.1a 4.5
Mice were treated with HuIFN-a (NI) or MuIFN-ac/, s.c. or
rHuIFN-y i.p. in 0.2ml BSA/PBSA daily for 4 days. Control mice
were injected with 0.2ml BSA/PBSA s.c. for 4 days. 6h after the last
injection the mice were killed and their lungs and spleen taken out
for assays. 6-8 mice were used per group. Each assay was performed
4 times on the post-mitochondrial 5-10 fraction. aThe 2-SA synthe-
tase activity in mice treated with MuIFN-ac/, was significantly
different from control mice (P=0.001); bThe 2-SA synthetase
activity in mice treated with MuIFN-a/,B was significantly different
from control mice (P=0.09).
Effect of HuIFN-cx (NJ) or rHuIFN-y on tumour cell
growth in vitro
Figure 3 shows a typical experiment in which DX3-azac cells
growing in Petri dishes as colonies were treated with varying
doses of HuIFN-ax (NI) or rHuIFN-y. With maximum
concentrations of 104 unitsml-1, the growth of DX3-azac
colonies was completely inhibited after 3 weeks of incuba-
tion. When cells were grown at higher cell densities (5 x 104
cells/dish) only a small amount of growth inhibition (33%)
was seen at the highest doses with each IFN (data not
shown).
Discussion
Therapy with HuIFN-cx (NI) or rHuIFN-y inhibited experi-
mental metastases of a human melanoma DX3-azac in
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Figure 3 The effect of HuIFN-oa (Nl) ( * ) and
rHuIFN-y ( * ) on colony number. DX3-azac were
plated at 103 cells/dish and medium and IFNs were changed
twice weekly. Colonies were counted after 3 weeks. Three dishes
were used per IFN dilution. Each experiment was performed 3
times.
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BALB/c nude mice and significantly increased the life span
of tumour bearing mice.
This inhibition appeared to be due to a direct cytostatic
effect on the tumour. DX3-azac cells were sensitive to the
growth inhibitory effects of IFNs in vitro when cells were
grown at low density but the human IFNs had no effect on
the nude mouse as measured by lung and spleen NK
activity, lung macrophage activity and haematological para-
meters. Moreover, the clearance of radiolabelled DX3-azac
cells was identical in control or treated mice confirming that
these HuIFNs had no effect on organ associated effector
cells. HuIFN-a (N1) had no significant effect on the 2-5A
synthetase levels in the lungs or spleens but rHuIFN-y
caused a small elevation.
Previous human tumour xenografts/nude mouse studies
with human IFNs (Balkwill, 1982, 1985) provided evidence
for a direct action of IFNs on subcutaneous tumours. The
experimental metastases model discussed here also demon-
strated that IFNs can have a direct inhibitory effect on the
growth of metastatic cells in the lungs.
IFNs could mediate their antitumour effect by direct
cytotasis or cytolysis of tumour cells.
IFNs could exert their antimetastatic effect by inducing
the differentiation of the tumour cells. IFNs can cause
differentiation of adipocytes and myocytes (Rossi, 1986).
However IFNs inhibited melangogenesis in cultured B16
melanoma cells (Fisher et al., 1981). In the DX3-azac
experiments carried out in this paper there was no increase
in melanin secretion in the tumour nodules of IFN treated
mice and no change in melanin production in IFN treated
cell cultures.
Classically, IFNs have mediated their antimetastatic effects
in immunocompetent mice only if given prophylactically, i.e.,
before tumour challenge. The inhibition of experimental
metastases has been suggested to be due to stimulation of
NK cells (Hanna & Burton, 1981; Brunda et al., 1984;
Nishimura et al., 1985). We have shown (Ramani et al.,
1986) that rHuIFN-oa A/D (an IFN that has activity on
murine cells) given after tumour challenge inhibited the
experimental metastases of COLON 26 in BALB/c mice and
Beige nude (T and NK cell deficient) mice. In addition, in
the COLON 26 model, an increased clearance of radio-
labelled tumour cells from the lungs was seen in IFN treated
mice. In contrast to the above studies, HuIFN a and y had
no effect on the clearance of DX3-azac cells from the lungs.
The exact mechanism by which HuIFN-o A/D inhibited the
experimental metastases of COLON 26 is not understood
but probably NK cells are not involved. Evidence suggests
that an early host-mediated mechanism may play a role in
IFNs antimetastatic effect in the COLON 26 model.
IFNs have therefore inhibited metastasis in several differ-
ent animal models. Metastasis is a complex process involving
several steps. It is possible that IFNs being pleiotropic
molecules influence several stages.
We conclude that in this model system IFNs have a direct
cytostatic effect on tumour cells, and that micrometastases
are sensitive to growth inhibitory effects of IFNs in vivo.
The authors wish to thank Dr Ian Hart for useful discussions, Dr
Jane Ormerod for the DX3-azac cells; and Elaine Moodie for
technical assistance with the animals.
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